New Medications Offer Hope for Alcohol Use Disorder
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
New Medications Offer Hope for Alcohol Use Disorder
- Three medications are currently approved by the U.S. Food and Drug Administration (FDA) to treat alcohol use disorder (AUD): naltrexone, acamprosate, and disulfiram.
- Naltrexone, available in oral and injectable forms, works by blocking opioid receptors in the brain, which reduces the pleasurable effects of alcohol and cravings.
Full Summary — powered by AI
For individuals struggling with alcohol use disorder (AUD), several medications offer a pathway to reducing or stopping alcohol consumption. The U.S. Food and Drug Administration (FDA) has approved three primary medications for AUD: naltrexone, acamprosate, and disulfiram.
Naltrexone, an opioid antagonist, is available as a daily oral pill or a monthly extended-release injection. It functions by blocking the opioid receptors in the brain, thereby reducing the euphoric feelings associated with drinking alcohol and decreasing cravings. Studies have indicated that naltrexone can help individuals with AUD reduce heavy drinking, and it can be prescribed while a patient is still drinking. It is not addictive and non-narcotic.
Acamprosate, another FDA-approved medication, helps individuals maintain abstinence after they have stopped drinking. Its exact mechanism of action is not fully understood, but it is thought to help restore the balance of certain brain neurotransmitters that are disrupted by chronic alcohol use, and it may reduce cravings. Acamprosate is typically started after a patient has completed alcohol withdrawal.
Disulfiram, often known by the brand name Antabuse, was the first medication approved for AUD. It works by causing highly unpleasant physical reactions—such as nausea, vomiting, and flushing—if a person consumes alcohol while taking it. This deters individuals from drinking. Disulfiram is generally used for patients committed to abstinence and is most effective when taken under supervision.
Beyond these three, other medications are sometimes used off-label to treat AUD, including topiramate and gabapentin, which may help reduce alcohol ingestion and cravings. Researchers are also exploring new avenues, such as genetically targeted therapies and psychedelic-derived compounds, with some showing promising results in clinical trials. These medications are often most effective when integrated into a comprehensive treatment plan that includes counseling and behavioral therapies.